Arbutus Biopharma Corp (NAS:ABUS)
$ 4.04 -0.01 (-0.25%) Market Cap: 762.68 Mil Enterprise Value: 624.18 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 51/100

Q1 2021 Arbutus Biopharma Corp Earnings Call Transcript

May 05, 2021 / 12:45PM GMT
Release Date Price: $2.96 (-11.11%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation 2021 First Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference to your speaker host today, Pam Murphy. Please go ahead.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Thank you, and good morning. On the call from Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dave Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with the review of the first quarter's accomplishment, clinical development and remaining 2021 corporate objectives, followed by Dave Hastings, who will provide a review of the company's first quarter financial results. We'll then open up the call for Q&A. Mike and Gaston will be available to address any research and clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot